Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

Kymab Ltd.. (6/3/14). "Press Release: Kymab Strengthens Management Team with Two Senior Appointments". Cambridge.

Product Product  MAb
Person Person Arkinstall, Steve (Kymab 201406– CSO before Merck Serono + Glaxo Wellcome)

Kymab, a monoclonal antibody biopharmaceutical company, announced today the appointment of Steve Arkinstall as Chief Scientific Officer and Nigel Clark as Vice President and Head of Business Development.

Christian Groendahl, CEO of Kymab, said: “Following the successful US$40 million fundraising in May, we are delighted to announce the appointments of Steve and Nigel to Kymab’s senior management team. Steve’s scientific know-how and expertise in developing high quality drugs at Merck Serono will enable us to further advance our proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need and will strengthen Kymab’s expertise in human genetics. Additionally, Nigel’s strong track record in deal making will be invaluable in maximising the potential of the Kymouse™ platform. We look forward to benefiting from both Steve and Nigel’s experience as we and build Kymab into a global biotechnology company.”

Steve Arkinstall brings overs 25 years’ experience across biopharmaceutical research and development, having worked across several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He joins Kymab from Merck Serono, where over his 16 year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of Global Technologies and External Innovation. Prior to joining Serono, he was in research at GlaxoWellcome. Steve is a respected leader in drug discovery and a global expert across a range of therapeutic, scientific and technical areas supporting drug discovery and development.

Allan Bradley, Founder and previously Chief Scientific Officer will continue as an essential member on the Executive Leadership team. He will serve as Chief Technology Officer driving further advances in Kymab’s proprietary technology platforms, strategic thinking in human population genetics and establishing a vaccine discovery capability. In addition, Allan will continue to serve as a member of the Board of Directors for Kymab.

Nigel Clark has 20 years’ experience in the biopharmaceutical industry at both public and private companies. He is a recognised deal maker and has completed over 20 major transactions. He was previously Chief Business Officer at Syntaxin and negotiated the sale of the company to Ipsen Pharma for €158 million. Prior to Syntaxin, Nigel was Head of Business Development at Vernalis, where he was responsible for commercial operations, a role he held for seven years.


About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse™ antibody discovery agreement was concluded with Novo Nordisk in 2013.

Founded in 2009, Kymab raised US$30 million of equity financing in 2010 from the investment division of the Wellcome Trust, and successfully raised US$40 million in a Series B financing in May 2014 from The Bill & Melinda Gates Foundation and an existing investor, the Wellcome Trust, each investing US$20 million. Kymab has an experienced management team with a successful track record in drug discovery and development and has 10 current therapeutic antibody discovery programmes in cancer and inflammation. For further information, please visit

About Kymab Access

Kymab is committed, with the support of its primary investor, The Wellcome Trust, to collaborate with leading academic experts. Kymab Access is a programme that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics or vaccines by partnering researchers with Kymab and its world leading Kymouse™ antibody technology. Kymab Access is administered by Kymab Access Limited, which is a wholly owned subsidiary of Kymab established solely for this purpose with a confidentiality firewall between its operations and those of Kymab.

For further information, please visit

For further information contact:

Christian Groendahl, Chief Executive Officer
Tel: +44 1223 833 301, Email:

Hume Brophy:
Mary Clark, Hollie Vile and Supriya Mathur
Tel: +44 (0)20 3440 5653, Email:

Kymab, Kymouse, Kymab Access are trademarks of Kymab Limited.

Record changed: 2017-01-13


Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for Kymab Group Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

» top